Is lorcaserin really associated with increased risk of cancer? A systematic review and meta‐analysis

Mesquita, Leonardo de Andrade; Piccoli, Giovana Fagundes; Natividade, Gabriella Richter da; Spiazzi, Bernardo Frison; Colpani, Verônica; Gerchman, Fernando

doi:10.1111/obr.13170

Cited by 24 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, patients treated with lorcaserin were diagnosed with more frequent occurrences of cancer. Indeed, incidences of malignancies during lorcaserin pharmacotherapy (though not different from the respective placebo groups) were the reason that it was withdrawn as an antiobesity medication in 2020 [ 125 , 126 , 127 ].…”

Section: Clinical Effects Of 5-ht 2c Receptor Agon...mentioning

confidence: 99%

5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators

et al. 2023

View full text Add to dashboard Cite

Obesity is a substantial health and economic issue, and serotonin (5-hydroxytryptamine, 5-HT) is an important neurotransmitter system involved in the regulation of body weight. The 5-HT2C receptors (5-HT2CRs), one of 16 of the 5-HT receptor (5-HTRs) subtypes, play a significant role in food intake and body weight control. In this review, we focused on the 5-HTR agonists, such as fenfluramines, sibutramine, and lorcaserin, which act directly or indirectly at 5-HT2CRs and have been introduced into the clinic as antiobesity medications. Due to their unwanted effects, they were withdrawn from the market. The 5-HT2CR positive allosteric modulators (PAMs) can be potentially safer active drugs than 5-HT2CR agonists. However, more in vivo validation of PAMs is required to fully determine if these drugs will be effective in obesity prevention and antiobesity pharmacology treatment. Methodology strategy: This review focuses on the role of 5-HT2CR agonism in obesity treatment, such as food intake regulation and weight gain. The literature was reviewed according to the review topic. We searched the PubMed and Scopus databases and Multidisciplinary Digital Publishing Institute open-access scientific journals using the following keyword search strategy depending on the chapter phrases: (1) “5-HT2C receptor” AND “food intake”, and (2) “5-HT2C receptor” AND “obesity” AND “respective agonists”, and (3) “5-HT2C receptor” AND “PAM”. We included preclinical studies (only present the weight loss effects) and double-blind, placebo-controlled, randomized clinical trials published since the 1975s (mostly related to antiobesity treatment), and excluded the pay-walled articles. After the search process, the authors selected, carefully screened, and reviewed appropriate papers. In total, 136 articles were included in this review.

show abstract

Section: Clinical Effects Of 5-ht 2c Receptor Agon...mentioning

confidence: 99%

5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[107][108][109] Unfortunately, lorcaserin has been removed from the market due to increased risk of cancer. 110 Also in 2012, the FDA approved the combination of phentermine (a methyl derivative of amphetamine) and topiramate (an anticonvulsant drug) as an adjuvant treatment for obesity in addition to diet and exercise. 111 In contrast, the European Medicines Agency has rejected this combination, citing concerns about long-term effects on the heart and blood vessels, mental health, and cognitive functions.…”

Section: Centurymentioning

confidence: 99%

“…In 2012, lorcaserin was registered in the United States (not in Europe), a drug acting on the 5‐hydroxytryptamine 2C receptor (5‐HT2C), which initially carried a low risk of side effects 107–109 . Unfortunately, lorcaserin has been removed from the market due to increased risk of cancer 110 . Also in 2012, the FDA approved the combination of phentermine (a methyl derivative of amphetamine) and topiramate (an anticonvulsant drug) as an adjuvant treatment for obesity in addition to diet and exercise 111 .…”

Section: Historical Overview Of Obesitymentioning

confidence: 99%

Historical and cultural aspects of obesity: From a symbol of wealth and prosperity to the epidemic of the 21st century

et al. 2022

View full text Add to dashboard Cite

Summary World Health Organization defines obesity as abnormal or excess adipose tissue accumulation. Nowadays, this condition is a serious threat to the public health in most countries around the world. Obesity adversely affects physical, mental, and in most cultures, social well‐being. However, throughout the ages—from ancient times to the 21st century—this condition has been subject to various interpretations. As a matter of fact, obesity has not always been regarded as a disease. For many decades, excessive body weight has been considered rather a symbol of health. It was a marker of wealth and prosperity, as well as a sign of high social status. The centuries that passed on the development of science and medicine have gradually changed its face, but significant progress in understanding the causes and consequences of obesity has been made in the last 30 years. This paper presents the historical outline of obesity and its treatment from ancient times to the present—from its affirmation to the epidemic in the late 20th and 21st century.

show abstract

“…There are also several antiobesity medications that are approved by the Food and Drug Administration (81). Relevant to cancer, lorcaserin was withdrawn from the market in February 2020 because of an increased risk of cancer (82,83).…”

Section: Interventions To Break the Link Between Obesity And Diabetes With Cancermentioning

confidence: 99%

The Triple Health Threat of Diabetes, Obesity, and Cancer—Epidemiology, Disparities, Mechanisms, and Interventions

Brown

Carson

Thompson

et al. 2021

Obesity

View full text Add to dashboard Cite

Obesity and type 2 diabetes are both chronic, relapsing, progressive diseases that are recognized as risk factors for the development of multiple types of cancer. In a recent symposium titled “Hitting A Triple—Diabetes, Obesity, and the Emerging Links to Cancer Risk,” convened by The Obesity Society during ObesityWeek 2019, experts in the field presented the current science and highlighted existing research gaps. Topics included (1) the epidemiology of obesity and diabetes and their links to cancer risk; (2) racial and ethnic differences in obesity, diabetes, and cancer risk; (3) biological mechanisms common to obesity and diabetes that may increase cancer risk; and (4) innovative interventions that can be used to prevent the development of cancers related to obesity and diabetes. This report provides an overview of the symposium and describes key research gaps and pressing questions in need of answers to advance the field. The collective burden of obesity, diabetes, and cancer represents one of the largest public health challenges of the century. Although the symposium was titled “hitting a triple,” it was recognized that being able to disrupt the linkages among obesity, diabetes, and cancer would be a “grand slam” for public health and medicine.

show abstract

Is lorcaserin really associated with increased risk of cancer? A systematic review and meta‐analysis

Cited by 24 publications

References 22 publications

5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators

5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators

Historical and cultural aspects of obesity: From a symbol of wealth and prosperity to the epidemic of the 21st century

The Triple Health Threat of Diabetes, Obesity, and Cancer—Epidemiology, Disparities, Mechanisms, and Interventions

Contact Info

Product

Resources

About